Sharps Technology Secures $400K Initial Purchase Order from U.S. Leader in IV Flushing Solutions as Part of $50 Million SoloGard Supply Agreement

Sharps Technology has received a $400,000 initial purchase order from a leading U.S. IV flushing solutions provider, marking its first commercial revenue under a previously announced $50 million supply agreement. The deal, established in July 2024, involves delivering approximately 500 million customized 10mL SoloGard syringes over five years. The company's Hungarian manufacturing facility is ready to fulfill these first orders, with strategic investments made in advanced production technology through partnerships with Husky Medical Molds and BBS Automation. These collaborations aim to streamline production processes and enhance manufacturing efficiency. CEO Robert Hayes describes this as a transformative moment for the company, signaling the transition from agreement to execution phase. The company expects to scale up production volume in coming quarters, leveraging precision molding and advanced automation to meet the growing demand under this significant contract.